@article{ref1,
title="Research progress in applications of selective serotonin reuptake inhibitors combined with other medicines in treatment-resistant depression",
journal="Chinese Journal of Pharmacology and Toxicology",
year="2022",
author="Wu, X.-l. and Wang, S.-y. and Zhao, S.-j. and Qin, X.-m. and Liu, X.-j.",
volume="36",
number="10",
pages="776-783",
abstract="Treatment-resistant depression (TRD) is a major depressive disorder that is often associated with more severe clinical symptoms, higher disability, and suicide risk than depression. Antide-pressant drugs are most often used for treating TRD in clinic, among which selective serotonin reuptake inhibitors (SSRI) have been mentioned as the first choice for the treatment of TRD in guidelines in many countries. However, due to the complex etiology and pathogenesis of TRD and numerous risk factors, the therapeutic effects of single drugs are far from satisfactory. Combined therapies exhibit syner-gistic effects, but reduce drug resistance, which have become the most important and effective strategy for TRD treatment in clinic. This paper reviews the available medication regimens and clinical efficacies of drug combination with SSRIs in treating TRD by focusing on the combination of SSRIs with chemical medicines, traditional Chinese medicines, and with other synergists so as to provide data for the selection of clinical treatment regimens for TRD and shed light on the internal mechanism of combating depression. © 2022 Chinese Journal of Pharmacology and Toxicology. All rights reserved.<p /><p>Language: zh</p>",
language="zh",
issn="1000-3002",
doi="10.3867/j.issn.1000-3002.2022.10.007",
url="http://dx.doi.org/10.3867/j.issn.1000-3002.2022.10.007"
}